T. Rowe Price Associates
PHAT icon

T. Rowe Price Associates’s Phathom Pharmaceuticals PHAT Stock Holding History

T. Rowe Price Associates’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$583K Buy
52,453
+15,382
+41% +$194K ﹤0.01% 2381
2025
Q4 		$616K Buy
37,071
+5,152
+16% +$73.6K ﹤0.01% 2298
2025
Q3 		$376K Buy
31,919
+1,815
+6% +$18.7K ﹤0.01% 2497
2025
Q2 		$289K Buy
30,104
+3,091
+11% +$17.1K ﹤0.01% 2548
2025
Q1 		$170K Buy
27,013
+1,372
+5% +$8.33K ﹤0.01% 2706
2024
Q4 		$209K Buy
25,641
+4,592
+22% +$56.9K ﹤0.01% 2659
2024
Q3 		$381K Buy
21,049
+474
+2% +$6.63K ﹤0.01% 2369
2024
Q2 		$212K Buy
20,575
+1,002
+5% +$10.3K ﹤0.01% 2575
2024
Q1 		$208K Buy
19,573
+2,172
+12% +$18.4K ﹤0.01% 2609
2023
Q4 		$159K Buy
17,401
+4,007
+30% +$34.5K ﹤0.01% 2609
2023
Q3 		$139K Sell
13,394
-38
-0.3% -$521 ﹤0.01% 2592
2023
Q2 		$193K Sell
13,432
-1,636
-11% -$18.9K ﹤0.01% 2545
2023
Q1 		$108K Buy
15,068
+118
+0.8% +$1.04K ﹤0.01% 2670
2022
Q4 		$168K Buy
14,950
+315
+2% +$3.25K ﹤0.01% 2587
2022
Q3 		$163K Buy
14,635
+4,295
+42% +$40.9K ﹤0.01% 2608
2022
Q2 		$87K Buy
+10,340
New +$106K ﹤0.01% 2783
2021
Q1 		– Sell
-81,021
Closed -$2.69M – 2868
2020
Q4 		$2.69M Sell
81,021
-59,441
-42% -$2.41M ﹤0.01% 1551
2020
Q3 		$5.15M Sell
140,462
-36,906
-21% -$1.28M ﹤0.01% 1399
2020
Q2 		$5.84M Buy
+177,368
New +$6.81M ﹤0.01% 1369

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

T. Rowe Price Associates's PHAT Position: Q1 2026 in Review

T. Rowe Price Associates increased its Phathom Pharmaceuticals (PHAT) stake by 41% in Q1 2026, buying an estimated $194K and bringing the position to 52,453 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #2381.

T. Rowe Price Associates first reported a position in PHAT in Q2 2020 and has held it in 19 quarters since. The position peaked at $5.84M in Q2 2020. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • T. Rowe Price Associates held 52,453 shares of Phathom Pharmaceuticals worth $583K as of Q1 2026.
  • T. Rowe Price Associates bought 15,382 Phathom Pharmaceuticals shares in Q1 2026, an estimated $194K.
  • Phathom Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2381 holding.
  • T. Rowe Price Associates first reported a position in Phathom Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Phathom Pharmaceuticals position peaked at $5.84M in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.